NO920945D0 - Nye 8-substituerte puriner som selektive adenosinreseptormidler - Google Patents

Nye 8-substituerte puriner som selektive adenosinreseptormidler

Info

Publication number
NO920945D0
NO920945D0 NO920945A NO920945A NO920945D0 NO 920945 D0 NO920945 D0 NO 920945D0 NO 920945 A NO920945 A NO 920945A NO 920945 A NO920945 A NO 920945A NO 920945 D0 NO920945 D0 NO 920945D0
Authority
NO
Norway
Prior art keywords
selective
new
substituted purines
receptor agents
adenosin
Prior art date
Application number
NO920945A
Other languages
English (en)
Other versions
NO920945L (no
NO300977B1 (no
Inventor
Norton Paul Peet
Nelsen Lowell Lentz
Mark William Dudley
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO920945D0 publication Critical patent/NO920945D0/no
Publication of NO920945L publication Critical patent/NO920945L/no
Publication of NO300977B1 publication Critical patent/NO300977B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO920945A 1991-03-12 1992-03-11 Nye 8-substituerte puriner som selektive adenosinreseptormidler NO300977B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/667,943 US5208240A (en) 1991-03-12 1991-03-12 8-substituted purines as selective adenosine receptor agents

Publications (3)

Publication Number Publication Date
NO920945D0 true NO920945D0 (no) 1992-03-11
NO920945L NO920945L (no) 1992-09-14
NO300977B1 NO300977B1 (no) 1997-08-25

Family

ID=24680310

Family Applications (1)

Application Number Title Priority Date Filing Date
NO920945A NO300977B1 (no) 1991-03-12 1992-03-11 Nye 8-substituerte puriner som selektive adenosinreseptormidler

Country Status (18)

Country Link
US (1) US5208240A (no)
EP (1) EP0503563B1 (no)
JP (1) JP3131275B2 (no)
KR (1) KR100220887B1 (no)
AT (1) ATE250059T1 (no)
AU (1) AU643599B2 (no)
CA (1) CA2062837C (no)
DE (1) DE69233202T2 (no)
DK (1) DK0503563T3 (no)
ES (1) ES2207631T3 (no)
FI (1) FI108721B (no)
HU (1) HU215923B (no)
IE (1) IE920787A1 (no)
IL (1) IL101186A (no)
NO (1) NO300977B1 (no)
NZ (1) NZ241890A (no)
PT (1) PT503563E (no)
ZA (1) ZA921715B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565566A (en) * 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
DE4129603A1 (de) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5521315A (en) * 1993-01-12 1996-05-28 Cell Therapeutics, Inc. Olefin substituted long chain compounds
CA2155130C (en) * 1993-02-26 1994-09-01 Janice M Hitchcock Xanthine derivatives as adenosine a1 receptor antagonists
NZ265790A (en) * 1993-05-06 1996-10-28 Merrell Dow Pharma 8-tetrahydronaphthyl or 2-phenyl-pentyl or -hexyl substituted xanthine derivatives and pharmaceutical compositions
FR2727315A1 (fr) * 1994-11-30 1996-05-31 Cooperative Agricole Laitiere Utilisation d'un decapeptide a activite de type benzodiazepine pour la preparation de medicaments et de complements alimentaires
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
EP0863148A1 (en) * 1997-03-03 1998-09-09 K.U. Leuven Research & Development Compounds derived from adenosine, use of such compound as a medicament, method for synthesizing such a compound and intermediates thereof
JP2002505687A (ja) 1997-06-18 2002-02-19 ディスカバリー セラピューティクス，インコーポレイテッド 脈管再生手順の後の再狭窄を防止するための組成物および方法
US5998386A (en) * 1997-09-19 1999-12-07 Feldman; Arthur M. Pharmaceutical compositions and method of using same for the treatment of failing myocardial tissue
US6060481A (en) * 1998-05-28 2000-05-09 The Penn State Research Foundation Method for improving insulin sensitivity using an adenosine receptor antagonist
HUP0103836A3 (en) * 1998-06-02 2003-05-28 Osi Pharmaceuticals Inc Uniond Pyrrolo[2,3d]pyrimidine compositions and their use
US6680322B2 (en) 1999-12-02 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US7732484B2 (en) 2000-08-01 2010-06-08 University Of Virginia Patent Foundation Use of selective adenosine A1 receptor allosteric enhancers to manipulate angiogenesis
US6680324B2 (en) * 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
JP2005529062A (ja) * 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アデノシンａ１及びａ３受容体に特異的な化合物とその使用
KR20040068317A (ko) 2001-12-20 2004-07-30 오에스아이 파마슈티컬스, 인코포레이티드 피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
JP2006518390A (ja) 2003-02-19 2006-08-10 エンダシア，インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
EP1636229A4 (en) 2003-06-06 2008-07-30 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
EP1636230A4 (en) * 2003-06-09 2010-06-16 Endacea Inc ADENOSINE A1 RECEPTOR ANTAGONISTS
WO2006099204A1 (en) * 2005-03-11 2006-09-21 Aderis Pharmaceuticals, Inc. Substituted 9-alkyladenines and the use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4397779A (en) * 1978-08-09 1983-08-09 Baxter Travenol Laboratories, Inc. Preparation of xanthine tracers
US4297494A (en) * 1978-08-09 1981-10-27 Baxter Travenol Laboratories, Inc. Xanthine tracers
EP0011399A1 (en) * 1978-11-11 1980-05-28 FISONS plc N-substituted theophyllines, processes for their preparation and pharmaceutical compositions containing them
US4452788A (en) * 1982-04-21 1984-06-05 Warner-Lambert Company Substituted 8-phenylxanthines
US4696932A (en) * 1984-10-26 1987-09-29 The United States Of America As Represented By The Department Of Health And Human Services Biologically-active xanthine derivatives
DE3522230A1 (de) * 1985-06-21 1987-01-02 Thomae Gmbh Dr K Neue 2-arylimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
HU197746B (en) * 1985-09-05 1989-05-29 Sandoz Ag Process for producing xantin derivatives and pharmaceutical compositions containing them
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5047534A (en) * 1990-03-26 1991-09-10 Merrell Dow Pharmaceuticals Inc. Selective adenosine receptor agents

Also Published As

Publication number Publication date
CA2062837C (en) 2002-08-27
KR100220887B1 (ko) 1999-09-15
HU215923B (hu) 1999-03-29
EP0503563B1 (en) 2003-09-17
NO920945L (no) 1992-09-14
NO300977B1 (no) 1997-08-25
DK0503563T3 (da) 2003-12-22
EP0503563A2 (en) 1992-09-16
ZA921715B (en) 1992-11-25
FI108721B (fi) 2002-03-15
NZ241890A (en) 1994-04-27
JP3131275B2 (ja) 2001-01-31
CA2062837A1 (en) 1992-09-13
IE920787A1 (en) 1992-09-23
HUT61022A (en) 1992-11-30
FI921052A0 (fi) 1992-03-11
DE69233202T2 (de) 2004-06-24
US5208240A (en) 1993-05-04
JPH05112568A (ja) 1993-05-07
ES2207631T3 (es) 2004-06-01
AU1213892A (en) 1992-09-17
ATE250059T1 (de) 2003-10-15
FI921052L (fi) 1992-09-13
IL101186A0 (en) 1992-11-15
PT503563E (pt) 2003-12-31
IL101186A (en) 1995-08-31
EP0503563A3 (en) 1992-12-02
AU643599B2 (en) 1993-11-18
KR920018053A (ko) 1992-10-21
DE69233202D1 (de) 2003-10-23
HU9200822D0 (en) 1992-05-28

Similar Documents

Publication Publication Date Title
NO920945L (no) Nye 8-substituerte puriner som selektive adenosinreseptormidler
CY1110512T1 (el) Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης
FI870113A0 (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten 4,5,6-substioitujenN-(substituoitu-fenyyli)-2-pyrimidiiniamiinien valmistamiseksi
DE69034103D1 (de) Imidazoalkensäure
ATE68495T1 (de) 4,5,6,7-tetrahydro-1h-imidazo(4,5c>pyridinderivate und analoge mit antihypertensiver wirkung.
ES2141787T3 (es) Derivados de la 1,2,3,4-tetrahidro-9-acridinamina.
ATE353328T1 (de) Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung
FI873428A7 (fi) Silmälääketieteelliset koostumukset hermodegeneraatioiden hoitoon.
DK0435177T3 (da) 4-Benzyl-5-phenyl-2,4-dihydro-3H-1,2,4-triazol-3-oner samt deres anvendelse som antikonvulsive midler
EE04040B1 (et) Aminotetraliini derivaat kardiovaskulaarsete haiguste raviks
ATE112168T1 (de) Menschlicher hitzeschock-faktor.
IT1225483B (it) Protesi ortopedica, particolarmente per la testa del femore.
IT1230135B (it) Procedimento per la preparazione dell'acido 3-idrossi-3-metilglutarico mediante ossidazione con ipoclorito del 3-metil-1,3,5pentantriolo.
IT8921913A0 (it) Procedimento per la preparazione dell'acido 3-idrossi-3-metilglutarico mediante ossidazione del 3-metil-1,3,5-pentantriolo
ES548849A0 (es) Mejoras en el objeto de la patente principal por procedimiento de obtencion de nuevos complejos de platino (ii) derivados del 1,1-ciclobutanodicarboxilato.
IT8620110A0 (it) Sistema per la regolazione dell'atina dei cestelli estraibili dei mobili, mediante angolari filettati.
ITRM910041A1 (it) Processo per la preparazione di cuoio non poroso impermeabile all'acqua utilizzabile per tomaie di calzature.
IT8622248A0 (it) Procedimento per la produzione di meta-clorobenzotrifluoruro mediante clorurazione catalitica del benzotrifluoruro.
DE3765250D1 (de) Verwendung von 24,25-dihydroxycholecalciferol zur behandlung von harnsteinen.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees